Clinical Trial Update: Effect of Exenatide on 24-Hour Blood Glucose Profile Compared With Placebo in Patients With Type 2 Diabetes [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluated the effect of exenatide on a 24-hour blood glucose profile compared with placebo in patients with Type 2 Diabetes Mellitus.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 2 Diabetes Mellitus

Drugs mentioned

• EXENATIDE (EXENATIDE)

Snippet

Sponsor: AstraZeneca | Conditions: Type 2 Diabetes Mellitus | Phase 2 | Status: COMPLETED